183 related articles for article (PubMed ID: 23680106)
1. Locally advanced prostate cancer: current controversies and optimisation opportunities.
Sridharan S; Dal Pra A; Catton C; Bristow RG; Warde P
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):499-505. PubMed ID: 23680106
[TBL] [Abstract][Full Text] [Related]
2. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
3. Locally advanced prostate cancer: effective treatments, but many adverse effects.
Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
[TBL] [Abstract][Full Text] [Related]
4. Evolving treatment paradigms for locally advanced and metastatic prostate cancer.
Dorff TB; Quek ML; Daneshmand S; Pinski J
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1639-51. PubMed ID: 17134367
[TBL] [Abstract][Full Text] [Related]
5. Current controversies in the treatment of high-risk prostate cancer.
Mitchell RE; Chang SS
Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235
[TBL] [Abstract][Full Text] [Related]
6. [Locally advanced prostate cancer: definition, prognosis and treatment].
Plantade A; Massard C; de Crevoisier R; Fizazi K
Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
8. The challenge of locally advanced prostate cancer.
Pisters LL
Semin Oncol; 1999 Apr; 26(2):202-16. PubMed ID: 10597731
[TBL] [Abstract][Full Text] [Related]
9. Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer.
Mannuel HD; Hussain A
Clin Genitourin Cancer; 2006 Jun; 5(1):43-9. PubMed ID: 16859578
[TBL] [Abstract][Full Text] [Related]
10. [Endocrine therapy for localized or locally advanced prostate cancer].
Fontaine E; Ruffion A; Staerman F
Prog Urol; 2004 Jun; 14(3):433-6. PubMed ID: 15373195
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
Roach M
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
[TBL] [Abstract][Full Text] [Related]
12. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
[TBL] [Abstract][Full Text] [Related]
13. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
14. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
15. [Controversy over treatment options in clinical T3 prostate cancer].
Nishimura K; Yamamoto Y; Nakayama M; Kakimoto K
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2548-52. PubMed ID: 22189219
[TBL] [Abstract][Full Text] [Related]
16. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
Mayer FJ; Crawford ED
Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
[TBL] [Abstract][Full Text] [Related]
17. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
Garzotto M; Wajsman Z
J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
[TBL] [Abstract][Full Text] [Related]
20. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
